We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

229 hedge funds and large institutions have $2.1B invested in Syndax Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 83 increasing their positions, 80 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more call options, than puts

Call options by funds: $30M | Put options by funds: $14.4M

35% more capital invested

Capital invested by funds: $1.56B → $2.1B (+$543M)

22% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 27

10% more funds holding in top 10

Funds holding in top 10: 10 → 11 (+1)

4% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 80

1% more funds holding

Funds holding: 227 → 229 (+2)

2.44% less ownership

Funds ownership: 117.38% → 114.94% (-2.4%)

Holders
229
Holders Change
+2
Holders Change %
+0.88%
% of All Funds
2.78%
Holding in Top 10
11
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+10%
% of All Funds
0.13%
New
33
Increased
83
Reduced
80
Closed
27
Calls
$30M
Puts
$14.4M
Net Calls
+$15.6M
Net Calls Change
+$3.08M

Top Buyers

1
HRCM
Hood River Capital Management
Florida
+$40.4M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$19M
3
Bank of America
Bank of America
North Carolina
+$17.7M
4
Ensign Peak Advisors
Ensign Peak Advisors
Utah
+$13.8M
5
State Street
State Street
Massachusetts
+$13M

Top Sellers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$51M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$30.4M
3
Millennium Management
Millennium Management
New York
-$17.3M
4
UBS Group
UBS Group
Switzerland
-$16.7M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$16.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$173M -$6.74M -386,242 -4%
KCM
2
Kynam Capital Management
New Jersey
$169M -$8.18M -469,041 -6%
Vanguard Group
3
Vanguard Group
Pennsylvania
$131M +$19M +1,091,717 +21%
Goldman Sachs
4
Goldman Sachs
New York
$120M +$3.65M +208,941 +4%
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$103M +$10.9M +627,006 +15%
Bank of America
6
Bank of America
North Carolina
$99M +$17.7M +1,012,993 +27%
State Street
7
State Street
Massachusetts
$96.6M +$13M +743,003 +19%
EP
8
Eversept Partners
New York
$69.6M -$2.67M -152,906 -4%
Franklin Resources
9
Franklin Resources
California
$50.9M +$543K +31,105 +1%
KCM
10
Kingdon Capital Management
New York
$49.4M -$2.62M -150,000 -6%
HRCM
11
Hood River Capital Management
Florida
$48.7M +$40.4M +2,316,553 New
SCM
12
Soleus Capital Management
Connecticut
$47.2M +$4.1M +235,000 +12%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$43.9M -$6.96K -399 -0%
EC
14
Elmind Capital
New York
$39M +$32.4M +1,855,000 New
Ensign Peak Advisors
15
Ensign Peak Advisors
Utah
$33.6M +$13.8M +789,480 +98%
N
16
Nuveen
North Carolina
$31.2M +$126K +7,204 +0.5%
BNP Paribas Asset Management
17
BNP Paribas Asset Management
France
$28.9M +$2.44M +139,604 +11%
SC
18
Stempoint Capital
New York
$28.1M -$468K -26,826 -2%
MB
19
MPM BioImpact
Massachusetts
$28.1M -$662K -37,972 -3%
ACM
20
Aisling Capital Management
New York
$27.7M – – –
WP
21
Woodline Partners
California
$26.3M -$5.23M -299,852 -19%
EAM
22
Eventide Asset Management
Massachusetts
$26M +$4.36M +249,710 +25%
D.E. Shaw & Co
23
D.E. Shaw & Co
New York
$25.6M +$2.48M +142,024 +13%
CCM
24
Catalio Capital Management
New York
$25.1M -$7.29M -417,910 -26%
Two Sigma Investments
25
Two Sigma Investments
New York
$24.1M +$7.58M +434,277 +61%
1
2 3 4 5

SNDX Hedge Fund Activity: Q4 2025 in Review

229 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2025, worth a combined $2.1B — up 35% from $1.56B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new SNDX positions and 27 closed out — a net gain of 6 holders — while 83 added to existing stakes and 80 trimmed.

The largest buyer was Hood River Capital Management, opening a new position worth an estimated $40.4M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $51M sold.

  • 229 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2025, up from 227 in Q3 2025.
  • Funds reported $2.1B of Syndax Pharmaceuticals stock for Q4 2025, up 35% quarter-over-quarter.
  • 33 funds opened new Syndax Pharmaceuticals positions in Q4 2025 and 27 closed out, a net change of +6 holders.
  • The largest Syndax Pharmaceuticals buyer in Q4 2025 was Hood River Capital Management, an estimated $40.4M added.
  • The largest Syndax Pharmaceuticals seller in Q4 2025 was Adage Capital Partners, an estimated $51M sold.

Based on aggregated 13F filings for Q4 2025.